Aptevo Therapeutics Inc (APVO)

$2.00 -0.04 (-1.96%)
Market Cap 1.51M
Revenue (ttm) 0.00
Net Income (ttm) -24.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 75,200
Avg Vol 2,753,948
Day's Range N/A - N/A
Shares Out 756,000.00
Stochastic %K 32%
Beta 5.64
Analysts Strong Buy
Price Target $420.00

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 838 0500
Fax: 206 838 0503
Address:
2401 4th Avenue, Suite 1050, Seattle, United States
jerrik
jerrik Aug. 14 at 7:35 PM
$APVO So interesting to me how these things wait until a specific low and then they move up so strongly. I saw 1.74 when this first did an R/S and ignored it but that's where it went to and now it's happy to move up. Algos probably.
0 · Reply
BLOCKS77
BLOCKS77 Aug. 14 at 7:17 PM
$APVO
0 · Reply
waeng
waeng Aug. 14 at 7:12 PM
$APVO
0 · Reply
DonZulu
DonZulu Aug. 14 at 4:24 PM
$APVO wait till Rate cuts the whole BIO sector in america has been fckin wrecked by bidens america and short algos
0 · Reply
RedDogSailor
RedDogSailor Aug. 14 at 4:17 PM
$APVO was that the bottom?
1 · Reply
digitalprofit3
digitalprofit3 Aug. 13 at 7:14 PM
$APVO crazy how we got scammed after all the funds they received
1 · Reply
Fozziethebear
Fozziethebear Aug. 13 at 12:15 PM
$APVO how do we move this bitch
0 · Reply
winwithme
winwithme Aug. 13 at 12:09 PM
$APVO volatile ✅
0 · Reply
MrTicker
MrTicker Aug. 13 at 12:06 PM
$APVO Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: Ayrton Capital LLC 10K WIZARD 5:29 AM ET 8/13/2025 http://archive.fast-edgar.com/20250813/AE2ZV22CZM22B2M5222I2WE2DTADZA22ZX72 Filed on: August 13, 2025
2 · Reply
Stock_Catcher
Stock_Catcher Aug. 13 at 12:05 PM
$APVO volume
0 · Reply
Latest News on APVO
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 13, 2025, 8:05 AM EDT - 4 days ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aug 11, 2025, 8:05 AM EDT - 6 days ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 11:30 AM EDT - 2 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:55 AM EDT - 2 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 20, 2025, 8:01 AM EDT - 2 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 1:34 PM EDT - 2 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 11:37 AM EDT - 2 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 10:52 AM EDT - 2 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 18, 2025, 8:01 AM EDT - 2 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Participating in the BIO International Convention

Jun 13, 2025, 8:05 AM EDT - 2 months ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025, 8:05 AM EDT - 3 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 15, 2025, 8:05 AM EDT - 3 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 8, 2025, 8:45 AM EDT - 3 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 22, 2025, 4:05 PM EDT - 4 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 4 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 4 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 4 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 20, 2025, 8:35 AM EDT - 5 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 18, 2025, 8:05 AM EDT - 5 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Aptevo to Participate in March Conferences

Mar 6, 2025, 8:00 AM EST - 5 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 15, 2025, 6:59 PM EST - 6 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Feb 14, 2025, 8:05 AM EST - 6 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Jan 15, 2025, 8:00 AM EST - 7 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 12:50 PM EST - 8 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 12, 2024, 9:00 AM EST - 8 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Dec 4, 2024, 8:35 AM EST - 9 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 29, 2024, 9:55 AM EST - 9 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 26, 2024, 8:35 AM EST - 9 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 22, 2024, 8:35 AM EST - 9 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 20, 2024, 8:35 AM EST - 9 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 11, 2024, 8:15 AM EST - 9 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 8:05 AM EST - 10 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 18, 2024, 4:05 PM EDT - 11 months ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 11 months ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 5, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Mar 4, 2024, 9:00 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Nov 14, 2023, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Aptevo to Present at Bio-Europe Conference

Nov 1, 2023, 7:45 AM EDT - 1 year ago

Aptevo to Present at Bio-Europe Conference

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Aug 10, 2023, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Aug 4, 2023, 6:40 PM EDT - 2 years ago

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

jerrik
jerrik Aug. 14 at 7:35 PM
$APVO So interesting to me how these things wait until a specific low and then they move up so strongly. I saw 1.74 when this first did an R/S and ignored it but that's where it went to and now it's happy to move up. Algos probably.
0 · Reply
BLOCKS77
BLOCKS77 Aug. 14 at 7:17 PM
$APVO
0 · Reply
waeng
waeng Aug. 14 at 7:12 PM
$APVO
0 · Reply
DonZulu
DonZulu Aug. 14 at 4:24 PM
$APVO wait till Rate cuts the whole BIO sector in america has been fckin wrecked by bidens america and short algos
0 · Reply
RedDogSailor
RedDogSailor Aug. 14 at 4:17 PM
$APVO was that the bottom?
1 · Reply
digitalprofit3
digitalprofit3 Aug. 13 at 7:14 PM
$APVO crazy how we got scammed after all the funds they received
1 · Reply
Fozziethebear
Fozziethebear Aug. 13 at 12:15 PM
$APVO how do we move this bitch
0 · Reply
winwithme
winwithme Aug. 13 at 12:09 PM
$APVO volatile ✅
0 · Reply
MrTicker
MrTicker Aug. 13 at 12:06 PM
$APVO Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: Ayrton Capital LLC 10K WIZARD 5:29 AM ET 8/13/2025 http://archive.fast-edgar.com/20250813/AE2ZV22CZM22B2M5222I2WE2DTADZA22ZX72 Filed on: August 13, 2025
2 · Reply
Stock_Catcher
Stock_Catcher Aug. 13 at 12:05 PM
$APVO volume
0 · Reply
DonZulu
DonZulu Aug. 13 at 12:07 AM
$APVO 85% remission in two lukemia trials with no wild side effects. Expecting some great news by EOY .
0 · Reply
d_risk
d_risk Aug. 12 at 1:06 AM
$APVO - Aptevo Therapeutics Inc. - 10Q - Updated Risk Factors APVO’s 10-Q risk factors highlight Nasdaq delisting risk, ongoing operating losses and going concern doubts, expanded financial and tax risks, new product liability and reimbursement threats, increased reliance on Medexus and third parties, detailed regulatory and data privacy exposures, and new competition from biosimilars and trademark challenges, while streamlining prior risk disclosures. #Biotechnology #MarketCompetition #ProductLiability #RegulatoryCompliance #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/APVO/10-Q/2025-08-11
1 · Reply
Champing
Champing Aug. 11 at 7:51 PM
$BTAI if you know what you have right there in your hands you won't allow sadist shorts to snatch it away from you. Bulls hold so tight ✊🏾. Those offerings are already in the shorts room I hear them screaming alas at themselves right now. They are crying heavily 😂 . They will cry more better 😂 we didn't ask to short us. You learnt your lesson? Haha 😂 There is no offering nor warrants here! Just gerrit.$ATNF $APVO $CETX $ONCO
1 · Reply
jerrik
jerrik Aug. 11 at 5:46 PM
$APVO CPI tomorrow. All the bios are down it seems but my tech stocks are not affected. I would have thought everything would be down today - the typical drama before market data comes out.
0 · Reply
JoseGilberto109
JoseGilberto109 Aug. 8 at 11:19 PM
Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $NWGL $PTLE $APVO $MRIN $LZMH recent banger
1 · Reply
jerrik
jerrik Aug. 8 at 3:45 PM
$APVO Interview with APVO COO this weekend to air at: https://www.redchip.com/media/3243/aptevo-therapeutics-inside-a-top-tier-oncology-pipeline-with-coo-jeff-lamothe I'm watching it right now (just create a login).
4 · Reply
DonZulu
DonZulu Aug. 7 at 8:30 PM
$APVO BOTTOM AF this cant even go lower 6$ rebound soon
0 · Reply
Bgreen999
Bgreen999 Aug. 7 at 1:59 PM
$APVO
1 · Reply
Bgreen999
Bgreen999 Aug. 6 at 7:16 PM
$APVO
0 · Reply
macstock
macstock Aug. 6 at 12:16 AM
$APVO this is the single worst performing non-bankrupt stock in the thousands of stocks listed on the nasdaq. And we still have pumpers. Amazing.
3 · Reply
macstock
macstock Aug. 5 at 11:55 PM
$APVO this chart says it all. Do not let pumpers here lie to you. Have them explain this. Probably the single worst value story I have ever seen in a non-bk company. And they are going to R/S again because they are not compliant and more dilution because they do not have enough cash….. run run run.
0 · Reply
MicrocapCowboy
MicrocapCowboy Aug. 5 at 4:17 PM
$APVO I know all about STX-428, Scorpion, and the other two clinical stage breast cancer acquisitions in the same 18 month period. Eli Lilly targeted them very specifically to compete with Roche and Pfizer more competitively in that space....it was about their need to pad their pipeline in that particular arena and the limited number of promising therapeutics available. I think we could go back and forth all day, but I won't waste anymore of your time since you adamantly disagree with me.....but if I'm right, I'll be sure to say so when that day comes.
1 · Reply